guy jud (@jud_guy) profile picture
Joined December 2017
Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)Photo by guy jud (@jud_guy)
Having some fun w Claude AI
1
159
$NMTC Never been in a stock lose so much value in one year on so little news: -86% YTD, $7.0 m market cap, $12.0 m sales, $2.0 m cash, $500k monthly cash burn (ugh) 2 FDA approved caths. Thank goodness it's a small position but doesnt make me feel less stupid
1
2
923
I figure it's either a tax loss or a significant add once the dilution/cap raise question is answered, likely the former though as I can't get comfy w some mgmt decisions. Would love to hear views from anyone who has deep dived co. and has a opinion, neg or pos
1
1
641
$KRMD Q3 was fine and looks like we will see acceleration resume Q4. FWIW I like the new CEO and was encouraged that Rystiggo contributed. They need a oncology deal to replace Phesgo as that's a very large opportunity. Secondary immunodeficiency also another growth leg IMO
1
220
$DCTH obviously a Q3 blowout. I think Q4 guidance is way too conservative given new starts. Love move into ICC (8x to 10x larger than mUm) w/ good historical evidence from IHP & CHEMOSTAT; cRc interim moved to mid 27 (from late 27); Believe CHOPIN add to NCCN still in cards
2
35
1,473
$DCTH Interesting that this patient received 2 HEPZATO treatments prior to beginning KIMMTRACK facebook.com/share/r/18ohCRc…
2
1
1
14
2,510
$DCTH My Q3 Est:$29.1 m ($27.1 m US) , assumes new patient starts were 0.7 Q1, 0.5 Q2, 0.2 Q3E; 4 repeat procedures per every 6 weeks @ $175K. 31 hospitals end of Q2 and 33 end of Q3. Est YE hospital activations from go from 37 year to 35.
1
12
1,319
$DCTH Revenue Recognition Schedule: Start Quarter: 1.0 kit ($175,000) Lag 1 Quarter: 1.5 kits ($262,500) Lag 2 Quarter: 1.5 kits ($262,500)
3
461
$NMTC (1) -81% YTD, -94.9% 5Y. CEO paid $787K;CFO gets $405K; CTO $333K . For an 18 person company, given the cash burn and the historical stock performance, egregious that top management gorges while shareholders bleed.
1
2
579
$NMTC (2)Bought small position , now a tiny position due to YTD decline . Blame myself , b/c mgmt always critical in micro , but I thought (and still feel) the tech itself has potential (and co. has approved products, $10 m revs, and drug delivery potential
1
1
205
$NMTC (3) Am surprised no pressure from the board or any institutional investors to replace top management, lower cash burn (inc salaries), and close deals w partners, and if all else fails, sell the company. Looking like a tax loss at this point sadly
1
2
165
🔬 Uveal melanoma is different from skin melanoma—and so are its treatment challenges. Explore insights from Dr. Marlana Orloff on emerging therapies, clinical trials, and personalized treatment decisions. 🔗 acureinsight.org/why-uveal-m…
4
643
I confess I have AI envy. These stocks go up every day. It must be boring to make $ so easily. At what point does everything AI get priced in or is each day a new surprise ? Oddly, when I was much younger, it was mentally easier to hold my nose and buy manias (dot com- hell yea)
2
162
$CGEM event.summitcast.com/view/9n… Maybe I’m missing something , but their decision to share all the data at once makes sense to me
2
2
652
FWIW I don’t see the shift as either a tell + or - but clearly market disagrees . Would love to also know how the stock moved -20% yesterday before the PR
1
113
The link lets you listen to $CGEM’s webcast at Stifel ( held 9/24)
1
261
$DCTH I believe CHOPIN protocol gets added to NCCN this fall as the cancer treatment guidelines are updated 1x a year typically and it’s been > 6 months since CHOPIN published so been plenty of time for review of data
2
15
1,995
$DCTH looks like Nebraska Medicine just became 32nd active REMS site for HEPZATO
19
1,619